From: UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression
All patients (N = 190) | |
---|---|
Age, M (Q1-Q3) | 63 (58-67) |
Race, n(%) | |
Non-black | 99 (52) |
Black | 91 (48) |
Year of Surgery, M (Q1-Q3) | 2001 (1997-2002) |
PSA (ng/mL), M (Q1-Q3) | 7.4 (5.1-11.1) |
Pathological Gleason, n(%): | |
2 – 6 | 39 (20) |
(3 + 4) | 100 (53) |
(4 + 3) – 10 | 51 (27) |
Positive Margins, n(%) | 115 (61) |
Seminal Vesicle Invasion, n(%) | 28 (15) |
Extracapsular Extension, n(%) | 51 (27) |
Positive Lymph Nodes, n(%) | 1 (<1) |
Average % Cells Positive for UGT2B15, M(Q1-Q3) | 39 (24-61) |
Average % Cells Positive for UGT2B17, M(Q1-Q3) | 74 (59-86) |
Average % Cells Positive for UGT2B28, M(Q1-Q3) | 77 (60-91) |
UGT2B15 H-score, M(Q1-Q3) | 40 (24-63) |
UGT2B17 H-score, M(Q1-Q3) | 76 (59-92) |
UGT2B28 H-score, M(Q1-Q3) | 86 (64-107) |
PSA Follow-up (months), M(Q1-Q3) | 118 (85-144) |